Concepts (318)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alzheimer Disease | 47 | 2023 | 1942 | 4.510 |
Why?
|
| Cognitive Dysfunction | 28 | 2023 | 938 | 3.100 |
Why?
|
| Stroke | 17 | 2023 | 293 | 2.900 |
Why?
|
| Cognition Disorders | 17 | 2015 | 1011 | 2.420 |
Why?
|
| Diet, Mediterranean | 8 | 2023 | 62 | 2.170 |
Why?
|
| Aged | 72 | 2023 | 9448 | 1.410 |
Why?
|
| Humans | 106 | 2023 | 29337 | 1.340 |
Why?
|
| Female | 72 | 2023 | 16197 | 1.260 |
Why?
|
| Cognition | 23 | 2023 | 1277 | 1.230 |
Why?
|
| Brain | 18 | 2023 | 1689 | 1.230 |
Why?
|
| Dementia | 9 | 2023 | 521 | 1.220 |
Why?
|
| Male | 68 | 2023 | 15621 | 1.180 |
Why?
|
| Biomarkers | 11 | 2023 | 689 | 1.150 |
Why?
|
| Aging | 11 | 2021 | 1593 | 1.120 |
Why?
|
| Aged, 80 and over | 39 | 2023 | 4851 | 1.050 |
Why?
|
| Chicago | 18 | 2021 | 865 | 1.020 |
Why?
|
| Stress, Psychological | 4 | 2016 | 246 | 0.990 |
Why?
|
| Ischemic Attack, Transient | 1 | 2023 | 20 | 0.890 |
Why?
|
| Diet, Western | 1 | 2022 | 6 | 0.870 |
Why?
|
| Depression | 3 | 2022 | 465 | 0.870 |
Why?
|
| Attitude | 1 | 2022 | 29 | 0.860 |
Why?
|
| Cardiology | 1 | 2022 | 73 | 0.800 |
Why?
|
| Amyloid beta-Peptides | 7 | 2023 | 294 | 0.800 |
Why?
|
| Community Participation | 1 | 2020 | 15 | 0.770 |
Why?
|
| Prospective Studies | 11 | 2023 | 1811 | 0.710 |
Why?
|
| Neuropsychological Tests | 13 | 2021 | 1251 | 0.710 |
Why?
|
| Longitudinal Studies | 21 | 2021 | 1442 | 0.680 |
Why?
|
| Hypertension | 6 | 2022 | 266 | 0.670 |
Why?
|
| tau Proteins | 6 | 2023 | 202 | 0.660 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2022 | 1221 | 0.660 |
Why?
|
| Brain Concussion | 3 | 2023 | 14 | 0.660 |
Why?
|
| Apolipoproteins E | 10 | 2023 | 230 | 0.650 |
Why?
|
| Football | 3 | 2023 | 36 | 0.640 |
Why?
|
| Disease Progression | 8 | 2023 | 787 | 0.640 |
Why?
|
| Nerve Fibers, Myelinated | 3 | 2013 | 39 | 0.600 |
Why?
|
| Risk Factors | 23 | 2023 | 2443 | 0.600 |
Why?
|
| Cerebrovascular Disorders | 3 | 2015 | 132 | 0.590 |
Why?
|
| Sex Characteristics | 4 | 2023 | 132 | 0.590 |
Why?
|
| Apolipoprotein E4 | 9 | 2021 | 227 | 0.590 |
Why?
|
| Independent Living | 5 | 2023 | 281 | 0.580 |
Why?
|
| Cohort Studies | 16 | 2023 | 1939 | 0.540 |
Why?
|
| Cerebral Infarction | 2 | 2013 | 152 | 0.490 |
Why?
|
| Cardiovascular Diseases | 4 | 2019 | 402 | 0.480 |
Why?
|
| Incidence | 12 | 2023 | 756 | 0.480 |
Why?
|
| Cross-Sectional Studies | 11 | 2022 | 959 | 0.460 |
Why?
|
| Dietary Approaches To Stop Hypertension | 3 | 2021 | 20 | 0.440 |
Why?
|
| Middle Aged | 18 | 2023 | 9823 | 0.430 |
Why?
|
| Dietary Supplements | 5 | 2022 | 53 | 0.420 |
Why?
|
| Brain Infarction | 2 | 2023 | 74 | 0.410 |
Why?
|
| Leukoencephalopathies | 1 | 2011 | 8 | 0.410 |
Why?
|
| Diet Surveys | 3 | 2022 | 19 | 0.400 |
Why?
|
| Sex Factors | 6 | 2023 | 496 | 0.390 |
Why?
|
| Ambulatory Care Facilities | 3 | 2022 | 37 | 0.390 |
Why?
|
| Smoking | 3 | 2012 | 194 | 0.370 |
Why?
|
| Neuroimaging | 4 | 2021 | 136 | 0.370 |
Why?
|
| Positron-Emission Tomography | 3 | 2023 | 88 | 0.360 |
Why?
|
| Neurodegenerative Diseases | 3 | 2023 | 117 | 0.360 |
Why?
|
| White Matter | 3 | 2022 | 149 | 0.340 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2021 | 441 | 0.340 |
Why?
|
| Genome-Wide Association Study | 4 | 2020 | 301 | 0.320 |
Why?
|
| Atrial Fibrillation | 2 | 2022 | 180 | 0.310 |
Why?
|
| Healthy Lifestyle | 3 | 2022 | 28 | 0.300 |
Why?
|
| Population Surveillance | 2 | 2021 | 116 | 0.300 |
Why?
|
| Cerebral Arteries | 1 | 2007 | 30 | 0.300 |
Why?
|
| Dementia, Vascular | 1 | 2007 | 41 | 0.290 |
Why?
|
| Vitamin B 6 | 1 | 2006 | 3 | 0.290 |
Why?
|
| Women's Health | 2 | 2019 | 246 | 0.290 |
Why?
|
| Vitamin B 12 | 1 | 2006 | 7 | 0.290 |
Why?
|
| Folic Acid | 1 | 2006 | 16 | 0.290 |
Why?
|
| Surveys and Questionnaires | 6 | 2022 | 1184 | 0.280 |
Why?
|
| Urban Health | 1 | 2006 | 23 | 0.280 |
Why?
|
| Diet | 5 | 2022 | 174 | 0.270 |
Why?
|
| Patient Selection | 2 | 2021 | 232 | 0.270 |
Why?
|
| Time Factors | 5 | 2021 | 1616 | 0.270 |
Why?
|
| Comorbidity | 5 | 2021 | 498 | 0.270 |
Why?
|
| Vitamin D | 2 | 2022 | 31 | 0.270 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2021 | 306 | 0.260 |
Why?
|
| Movement Disorders | 1 | 2006 | 141 | 0.260 |
Why?
|
| Proportional Hazards Models | 5 | 2015 | 340 | 0.250 |
Why?
|
| Overweight | 2 | 2022 | 65 | 0.250 |
Why?
|
| Risk Assessment | 7 | 2022 | 679 | 0.250 |
Why?
|
| Parkinson Disease | 4 | 2022 | 1164 | 0.240 |
Why?
|
| Early Diagnosis | 2 | 2020 | 65 | 0.240 |
Why?
|
| Day Care, Medical | 3 | 2008 | 5 | 0.230 |
Why?
|
| Risk | 5 | 2015 | 217 | 0.230 |
Why?
|
| Emergency Medical Services | 2 | 2020 | 35 | 0.230 |
Why?
|
| Follow-Up Studies | 8 | 2021 | 1830 | 0.220 |
Why?
|
| Gender Identity | 2 | 2023 | 21 | 0.220 |
Why?
|
| Exercise | 3 | 2022 | 468 | 0.220 |
Why?
|
| Life Style | 5 | 2023 | 211 | 0.220 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2022 | 194 | 0.220 |
Why?
|
| Crime Victims | 1 | 2022 | 23 | 0.210 |
Why?
|
| Food | 1 | 2022 | 28 | 0.210 |
Why?
|
| United States | 8 | 2022 | 2333 | 0.210 |
Why?
|
| Health Status Disparities | 2 | 2019 | 69 | 0.210 |
Why?
|
| Genetic Testing | 1 | 2022 | 64 | 0.210 |
Why?
|
| Genetic Loci | 3 | 2020 | 61 | 0.210 |
Why?
|
| Lutein | 1 | 2021 | 2 | 0.210 |
Why?
|
| Zeaxanthins | 1 | 2021 | 2 | 0.210 |
Why?
|
| Carotenoids | 1 | 2021 | 9 | 0.210 |
Why?
|
| Healthcare Disparities | 2 | 2019 | 75 | 0.210 |
Why?
|
| Causality | 3 | 2011 | 53 | 0.200 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2020 | 12 | 0.190 |
Why?
|
| Neurofilament Proteins | 1 | 2020 | 6 | 0.190 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2020 | 31 | 0.190 |
Why?
|
| Program Development | 1 | 2020 | 69 | 0.190 |
Why?
|
| Endothelium | 1 | 2020 | 12 | 0.190 |
Why?
|
| Membrane Proteins | 1 | 2021 | 173 | 0.180 |
Why?
|
| Terminal Care | 1 | 2020 | 27 | 0.180 |
Why?
|
| Advance Care Planning | 1 | 2020 | 16 | 0.180 |
Why?
|
| Vascular Diseases | 1 | 2020 | 48 | 0.180 |
Why?
|
| Genotype | 4 | 2016 | 405 | 0.180 |
Why?
|
| Heart Failure, Diastolic | 1 | 2018 | 2 | 0.170 |
Why?
|
| Parkinsonian Disorders | 1 | 2022 | 217 | 0.170 |
Why?
|
| Women's Health Services | 1 | 2018 | 12 | 0.170 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2018 | 17 | 0.170 |
Why?
|
| Cardiovascular Agents | 1 | 2018 | 28 | 0.170 |
Why?
|
| Patient Care Management | 1 | 2018 | 18 | 0.170 |
Why?
|
| Multiple Sclerosis | 2 | 2010 | 87 | 0.170 |
Why?
|
| Culturally Competent Care | 1 | 2018 | 9 | 0.160 |
Why?
|
| American Heart Association | 1 | 2018 | 29 | 0.160 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2018 | 26 | 0.160 |
Why?
|
| Emigrants and Immigrants | 1 | 2018 | 20 | 0.160 |
Why?
|
| Mortality | 2 | 2016 | 86 | 0.160 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2018 | 42 | 0.160 |
Why?
|
| Emergency Medical Service Communication Systems | 1 | 2017 | 1 | 0.160 |
Why?
|
| Amyloid | 3 | 2022 | 53 | 0.160 |
Why?
|
| Public Health | 1 | 2018 | 60 | 0.150 |
Why?
|
| Fibrinolytic Agents | 1 | 2018 | 56 | 0.150 |
Why?
|
| Self Report | 2 | 2022 | 218 | 0.150 |
Why?
|
| Atherosclerosis | 1 | 2018 | 72 | 0.150 |
Why?
|
| Prevalence | 4 | 2021 | 487 | 0.150 |
Why?
|
| Homes for the Aged | 2 | 2007 | 9 | 0.150 |
Why?
|
| Cognitive Aging | 1 | 2018 | 81 | 0.150 |
Why?
|
| Linear Models | 2 | 2015 | 254 | 0.140 |
Why?
|
| Nursing Homes | 2 | 2007 | 38 | 0.140 |
Why?
|
| Lipoprotein(a) | 1 | 2016 | 5 | 0.140 |
Why?
|
| Adult | 9 | 2023 | 8601 | 0.140 |
Why?
|
| Communication | 1 | 2017 | 111 | 0.140 |
Why?
|
| Health Promotion | 1 | 2018 | 161 | 0.140 |
Why?
|
| Dyslipidemias | 1 | 2016 | 23 | 0.140 |
Why?
|
| Age Factors | 4 | 2019 | 843 | 0.130 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 31 | 0.130 |
Why?
|
| Psychological Tests | 1 | 2015 | 52 | 0.130 |
Why?
|
| Clergy | 2 | 2006 | 90 | 0.130 |
Why?
|
| Models, Genetic | 1 | 2015 | 35 | 0.130 |
Why?
|
| Logistic Models | 3 | 2011 | 407 | 0.130 |
Why?
|
| Age Distribution | 2 | 2011 | 94 | 0.130 |
Why?
|
| Interviews as Topic | 1 | 2015 | 130 | 0.130 |
Why?
|
| Interpersonal Relations | 2 | 2015 | 105 | 0.120 |
Why?
|
| Survival Analysis | 1 | 2015 | 298 | 0.120 |
Why?
|
| Tissue Donors | 2 | 2012 | 74 | 0.120 |
Why?
|
| Odds Ratio | 2 | 2011 | 285 | 0.120 |
Why?
|
| Patient Compliance | 1 | 2015 | 164 | 0.120 |
Why?
|
| Antioxidants | 2 | 2005 | 56 | 0.120 |
Why?
|
| Heart Failure | 3 | 2022 | 202 | 0.120 |
Why?
|
| Intermediate Filaments | 2 | 2023 | 17 | 0.110 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2015 | 343 | 0.110 |
Why?
|
| Residence Characteristics | 2 | 2011 | 216 | 0.110 |
Why?
|
| Patient Dropouts | 1 | 2012 | 27 | 0.110 |
Why?
|
| Bias | 1 | 2012 | 33 | 0.110 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 521 | 0.100 |
Why?
|
| Prognosis | 3 | 2019 | 840 | 0.100 |
Why?
|
| Sex Distribution | 1 | 2011 | 87 | 0.100 |
Why?
|
| Social Support | 1 | 2012 | 185 | 0.100 |
Why?
|
| Blood Pressure | 2 | 2022 | 238 | 0.100 |
Why?
|
| Alleles | 3 | 2021 | 224 | 0.100 |
Why?
|
| Neocortex | 1 | 2010 | 34 | 0.100 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2010 | 5 | 0.090 |
Why?
|
| Qualitative Research | 2 | 2023 | 112 | 0.090 |
Why?
|
| Interleukin-7 | 1 | 2010 | 19 | 0.090 |
Why?
|
| Gene Frequency | 1 | 2010 | 75 | 0.090 |
Why?
|
| Interferon Regulatory Factors | 1 | 2009 | 2 | 0.090 |
Why?
|
| Lewy Body Disease | 1 | 2010 | 98 | 0.090 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2009 | 17 | 0.090 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2009 | 8 | 0.090 |
Why?
|
| Diabetes Mellitus | 2 | 2022 | 138 | 0.090 |
Why?
|
| Coronary Artery Disease | 2 | 2022 | 123 | 0.090 |
Why?
|
| Antigens, CD | 1 | 2009 | 99 | 0.090 |
Why?
|
| Retrospective Studies | 4 | 2021 | 3273 | 0.090 |
Why?
|
| Psychometrics | 1 | 2010 | 262 | 0.080 |
Why?
|
| Brain Mapping | 1 | 2010 | 195 | 0.080 |
Why?
|
| Community Health Services | 1 | 2009 | 31 | 0.080 |
Why?
|
| Confidence Intervals | 2 | 2005 | 96 | 0.080 |
Why?
|
| Community Health Nursing | 1 | 2008 | 11 | 0.080 |
Why?
|
| Geriatric Assessment | 3 | 2021 | 219 | 0.080 |
Why?
|
| Home Care Services | 1 | 2008 | 20 | 0.080 |
Why?
|
| Vitamin E | 2 | 2005 | 27 | 0.080 |
Why?
|
| Life Expectancy | 2 | 2022 | 19 | 0.080 |
Why?
|
| Signal Transduction | 1 | 2010 | 482 | 0.080 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2007 | 16 | 0.080 |
Why?
|
| Education | 1 | 2006 | 39 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 1 | 2006 | 96 | 0.070 |
Why?
|
| Decision Support Techniques | 1 | 2006 | 52 | 0.070 |
Why?
|
| Quality of Life | 2 | 2022 | 662 | 0.070 |
Why?
|
| Patient Admission | 1 | 2005 | 27 | 0.070 |
Why?
|
| Research Design | 2 | 2021 | 212 | 0.070 |
Why?
|
| Case-Control Studies | 3 | 2015 | 638 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2007 | 389 | 0.070 |
Why?
|
| Tocopherols | 1 | 2005 | 6 | 0.070 |
Why?
|
| Memory | 2 | 2006 | 318 | 0.060 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2023 | 6 | 0.060 |
Why?
|
| Seafood | 1 | 2003 | 10 | 0.060 |
Why?
|
| Caloric Restriction | 1 | 2023 | 11 | 0.060 |
Why?
|
| Memory Disorders | 2 | 2019 | 174 | 0.060 |
Why?
|
| Dietary Fats | 1 | 2003 | 24 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2006 | 200 | 0.060 |
Why?
|
| Diet, Vegetarian | 1 | 2022 | 3 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 324 | 0.060 |
Why?
|
| Vitamins | 1 | 2022 | 17 | 0.060 |
Why?
|
| Fraud | 1 | 2022 | 21 | 0.050 |
Why?
|
| Polypharmacy | 1 | 2022 | 10 | 0.050 |
Why?
|
| Anthocyanins | 1 | 2022 | 7 | 0.050 |
Why?
|
| Vitamin K | 1 | 2022 | 8 | 0.050 |
Why?
|
| Motivation | 1 | 2023 | 100 | 0.050 |
Why?
|
| Fruit | 1 | 2022 | 25 | 0.050 |
Why?
|
| Survivors | 1 | 2022 | 57 | 0.050 |
Why?
|
| Vegetables | 1 | 2021 | 16 | 0.050 |
Why?
|
| Secondary Prevention | 1 | 2022 | 64 | 0.050 |
Why?
|
| Primary Prevention | 1 | 2022 | 38 | 0.050 |
Why?
|
| Frailty | 1 | 2022 | 38 | 0.050 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2022 | 52 | 0.050 |
Why?
|
| Atrial Appendage | 1 | 2022 | 45 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2022 | 144 | 0.050 |
Why?
|
| Probability | 1 | 2021 | 94 | 0.050 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2022 | 104 | 0.050 |
Why?
|
| Alcohol Drinking | 1 | 2022 | 78 | 0.050 |
Why?
|
| Accelerometry | 1 | 2021 | 87 | 0.050 |
Why?
|
| Weight Loss | 1 | 2022 | 99 | 0.050 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2020 | 7 | 0.050 |
Why?
|
| Athletes | 1 | 2021 | 76 | 0.050 |
Why?
|
| Catheter Ablation | 1 | 2022 | 78 | 0.050 |
Why?
|
| Neurofibrillary Tangles | 1 | 2022 | 181 | 0.050 |
Why?
|
| Anticoagulants | 1 | 2022 | 100 | 0.050 |
Why?
|
| Medical History Taking | 1 | 2020 | 24 | 0.050 |
Why?
|
| Executive Function | 1 | 2021 | 121 | 0.050 |
Why?
|
| Self-Assessment | 1 | 2020 | 29 | 0.050 |
Why?
|
| Tremor | 1 | 2022 | 141 | 0.050 |
Why?
|
| Accidental Falls | 1 | 2022 | 116 | 0.050 |
Why?
|
| Illinois | 1 | 2021 | 241 | 0.050 |
Why?
|
| Hospital Mortality | 1 | 2021 | 141 | 0.050 |
Why?
|
| Coronary Circulation | 1 | 2020 | 43 | 0.050 |
Why?
|
| Young Adult | 2 | 2020 | 1932 | 0.050 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2020 | 81 | 0.050 |
Why?
|
| Cardiovascular System | 1 | 2019 | 14 | 0.040 |
Why?
|
| Autopsy | 1 | 2021 | 335 | 0.040 |
Why?
|
| Nutrition Assessment | 3 | 2005 | 31 | 0.040 |
Why?
|
| Survival Rate | 2 | 2011 | 349 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2018 | 3478 | 0.040 |
Why?
|
| Cerebral Cortex | 1 | 2020 | 195 | 0.040 |
Why?
|
| Epidemiologic Studies | 2 | 2012 | 23 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2019 | 227 | 0.040 |
Why?
|
| Asia, Western | 1 | 2018 | 2 | 0.040 |
Why?
|
| Indian Ocean Islands | 1 | 2018 | 2 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2021 | 301 | 0.040 |
Why?
|
| Hippocampus | 1 | 2020 | 274 | 0.040 |
Why?
|
| Caregivers | 1 | 2020 | 143 | 0.040 |
Why?
|
| Hospitalization | 1 | 2021 | 317 | 0.040 |
Why?
|
| Cultural Characteristics | 1 | 2018 | 21 | 0.040 |
Why?
|
| Focus Groups | 1 | 2018 | 84 | 0.040 |
Why?
|
| Ambulances | 1 | 2017 | 1 | 0.040 |
Why?
|
| Animals | 2 | 2018 | 4552 | 0.040 |
Why?
|
| Pregnancy | 1 | 2018 | 403 | 0.040 |
Why?
|
| Models, Statistical | 2 | 2012 | 132 | 0.040 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2020 | 202 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 208 | 0.040 |
Why?
|
| Oncogene Protein v-akt | 1 | 2016 | 12 | 0.040 |
Why?
|
| Registries | 1 | 2018 | 188 | 0.040 |
Why?
|
| Health Status | 1 | 2018 | 227 | 0.040 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 48 | 0.040 |
Why?
|
| Breast Feeding | 1 | 2018 | 155 | 0.040 |
Why?
|
| Georgia | 1 | 2016 | 12 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2016 | 30 | 0.040 |
Why?
|
| Diagnosis | 1 | 2015 | 23 | 0.030 |
Why?
|
| Phenotype | 1 | 2016 | 355 | 0.030 |
Why?
|
| Chromosomes, Human | 1 | 2015 | 7 | 0.030 |
Why?
|
| Educational Status | 2 | 2007 | 295 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2016 | 174 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2015 | 41 | 0.030 |
Why?
|
| Lewy Bodies | 1 | 2015 | 195 | 0.030 |
Why?
|
| Medicare | 1 | 2014 | 121 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2009 | 1113 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2014 | 330 | 0.030 |
Why?
|
| Markov Chains | 1 | 2012 | 29 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 724 | 0.030 |
Why?
|
| Phenanthrolines | 1 | 2010 | 4 | 0.020 |
Why?
|
| Carbon Radioisotopes | 1 | 2010 | 7 | 0.020 |
Why?
|
| Peptidylprolyl Isomerase | 1 | 2010 | 6 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2010 | 59 | 0.020 |
Why?
|
| Aniline Compounds | 1 | 2010 | 41 | 0.020 |
Why?
|
| Thiazoles | 1 | 2010 | 35 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2010 | 105 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 58 | 0.020 |
Why?
|
| Nursing Administration Research | 1 | 2008 | 5 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2008 | 47 | 0.020 |
Why?
|
| Nursing Assessment | 1 | 2008 | 44 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2008 | 67 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2008 | 328 | 0.020 |
Why?
|
| Spatial Behavior | 1 | 2006 | 14 | 0.020 |
Why?
|
| Visual Acuity | 1 | 2006 | 42 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2007 | 123 | 0.020 |
Why?
|
| Patient Transfer | 1 | 2005 | 20 | 0.020 |
Why?
|
| Cross-Cultural Comparison | 1 | 2005 | 42 | 0.020 |
Why?
|
| Mental Status Schedule | 1 | 2005 | 113 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2006 | 132 | 0.020 |
Why?
|
| gamma-Tocopherol | 1 | 2005 | 7 | 0.020 |
Why?
|
| alpha-Tocopherol | 1 | 2005 | 9 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 333 | 0.020 |
Why?
|
| Adolescent | 1 | 2010 | 2279 | 0.010 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2003 | 7 | 0.010 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2003 | 7 | 0.010 |
Why?
|
| Docosahexaenoic Acids | 1 | 2003 | 8 | 0.010 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2003 | 15 | 0.010 |
Why?
|
| beta Carotene | 1 | 2002 | 7 | 0.010 |
Why?
|
| Ascorbic Acid | 1 | 2002 | 32 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2002 | 52 | 0.010 |
Why?
|
| Urban Population | 1 | 2003 | 143 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2002 | 124 | 0.010 |
Why?
|